UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2018

 

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM __________ TO __________

 

COMMISSION FILE NUMBER: 000-54819

 

BIOSOLAR, INC.

(Name of registrant in its charter)

 

Nevada		20-4754291
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

 

27936 Lost Canyon Road, Suite 202, Santa Clarita, CA 91387

(Address of principal executive offices) (Zip Code)

 

Issuer’s telephone Number: (661) 251-0001

 

Indicate by check mark whether the registrant (1) has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒  No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐  No ☒

 

The number of shares of registrant’s common stock issued and outstanding as of July 30, 2018 was 56,930,392.

 

 

BIOSOLAR, INC.

INDEX

 

		Page
PART I: FINANCIAL INFORMATION		1
ITEM 1	FINANCIAL STATEMENTS (Unaudited)	1
	Condensed Balance Sheets	1
	Condensed Statements of Operations	2
	Condensed Statement of Shareholders’ Deficit	3
	Condensed Statements of Cash Flows	4
	Notes to the Condensed Financial Statements	5
ITEM 2	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	11
ITEM 3	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	15
ITEM 4	CONTROLS AND PROCEDURES	15
PART II: OTHER INFORMATION		16
ITEM 1	LEGAL PROCEEDINGS	16
ITEM 1A	RISK FACTORS	16
ITEM 2	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	16
ITEM 3	DEFAULTS UPON SENIOR SECURITIES	16
ITEM 4	MINE SAFETY DISCLOSURES	16
ITEM 5	OTHER INFORMATION	16
ITEM 6	EXHIBITS	17
SIGNATURES		18

 

  

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

BIOSOLAR, INC.

CONDENSED BALANCE SHEETS

 

		June 30, 2018				December 31, 2017
		(Unaudited)
ASSETS
CURRENT ASSETS
Cash		$	112,941			$	119,446
Prepaid expenses			33,074				21,644
TOTAL CURRENT ASSETS			146,015				141,090
PROPERTY AND EQUIPMENT
Machinery and equipment			37,225				31,455
Less accumulated depreciation			(25,371	)			(23,733	)
NET PROPERTY AND EQUIPMENT			11,854				7,722
OTHER ASSETS
Patents, net of amortization of $7,751 and $6,045, respectively			67,736				69,442
Deposit			770				770
TOTAL OTHER ASSETS			68,506				70,212
TOTAL ASSETS		$	226,375			$	219,024
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable		$	13,333			$	31,845
Accrued expenses			499,158				414,702
Derivative liability			34,784,811				5,239,073
Convertible promissory notes net of debt discount of $72,301 and $5,340, respectively			157,699				396,660
TOTAL CURRENT LIABILITIES			35,455,001				6,082,280
LONG TERM LIABILITIES
Convertible promissory notes net of debt discount of $1,217 and $351, respectively			2,205,003				1,791,279
TOTAL LONG TERM LIABILITIES			2,205,003				1,791,279
TOTAL LIABILITIES			37,660,004				7,873,559
SHAREHOLDERS' DEFICIT
Preferred stock, $0.0001 par value; 10,000,000 authorized common shares			-				-
Common stock, $0.0001 par value; 500,000,000 authorized common shares 56,930,392 and 41,485,051 shares issued and outstanding, respectively			5,693				4,149
Additional paid in capital			11,476,662				11,127,693
Accumulated deficit			(48,915,984	)			(18,786,377	)
TOTAL SHAREHOLDERS' DECIFIT			(37,433,629	)			(7,654,535	)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT		$	226,375			$	219,024

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

BIOSOLAR, INC.

CONDENSED STATEMENTS OF OPERATIONS

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2018 AND 2017

(Unaudited)

 

		Three Months Ended								Six Months Ended
		June 30, 2018				June 30, 2017				June 30, 2018				June 30, 2017
REVENUE		$	-			$	-			$	-			$	-
OPERATING EXPENSES
General and administrative expenses			107,677				476,472				203,608				973,170
Research and development			40,041				42,008				93,441				61,559
Depreciation and amortization			1,809				831				3,343				1,661
TOTAL OPERATING EXPENSES			149,527				519,311				300,392				1,036,390
LOSS FROM OPERATIONS BEFORE  OTHER INCOME (EXPENSES)			(149,527	)			(519,311	)			(300,392	)			(1,036,390	)
TOTAL OTHER INCOME/(EXPENSES)
Interest income			7				10				13				22
Loss on settlement of debt			(71,258	)			(244,967	)			(234,733	)			(244,967	)
Loss on change in derivative liability			(29,268,085	)			(819,897	)			(29,464,894	)			(535,090	)
Interest expense			(68,424	)			(85,070	)			(129,601	)			(223,693	)
TOTAL OTHER (EXPENSES) INCOME			(29,407,760	)			(1,149,924	)			(29,829,215	)			(1,003,728	)
NET LOSS		$	(29,557,287	)		$	(1,669,235	)		$	(30,129,607	)		$	(2,040,118	)
BASIC AND DILUTED LOSS PER SHARE		$	(0.56	)		$	(0.05	)		$	(0.62	)		$	(0.06	)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED			52,917,851				34,437,017				48,885,588				32,749,156

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

  

BIOSOLAR, INC.

CONDENSED STATEMENT OF SHAREHOLDERS’ DEFICIT

FOR THE SIX MONTHS ENDED JUNE 30, 2018

 

																		Additional
		Preferred Stock								Common Stock								Paid-in				Accumulated
		Shares				Amount				Shares				Amount				Capital				Deficit				Total
Balance at December 31, 2017			-			$	-				41,485,051			$	4,149			$	11,127,693			$	(18,786,377	)		$	(7,654,535	)
Issuance of common shares for converted promissory notes and accrued interest			-				-				15,445,341				1,544				348,969				-				350,513
Net Loss			-				-				-				-				-				(30,129,607	)			(30,129,607	)
Balance at June 30, 2018 (Unaudited)			-			$	-				56,930,392			$	5,693			$	11,476,662			$	(48,915,984	)		$	(37,433,629	)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

  

BIOSOLAR, INC.

CONDENSED STATEMENTS OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

(Unaudited)

 

		Six Months Ended
		June 30, 2018				June 30, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss		$	(30,129,607	)		$	(2,040,118	)
Adjustment to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense			3,343				1,661
Stock based compensation			-				771,027
Loss on net change in derivative liability			29,464,894				535,090
Loss on settlement of debt			234,733				244,967
Amortization of debt discount recognized as interest expense			13,016				128,586
(Increase) Decrease in Changes in Assets
Prepaid expenses			(11,430	)			(12,339	)
Increase (Decrease) in Changes in Liabilities
Accounts payable			(18,512	)			(3,143	)
Accrued expenses			114,828				94,193
NET CASH USED IN OPERATING ACTIVITIES			(328,735	)			(280,076	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment			(5,770	)			-
Patent expenditures			-				(482	)
NET CASH USED IN INVESTING ACTIVITIES			(5,770	)			(482	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes			328,000				253,000
NET CASH PROVIDED BY FINANCING ACTIVITIES			328,000				253,000
NET DECREASE IN CASH			(6,505	)			(27,558	)
CASH, BEGINNING OF PERIOD			119,446				208,629
CASH, END OF PERIOD		$	112,941			$	181,071
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid		$	1,759			$	790
Taxes paid		$	-			$	-
SUPPLEMENTAL SCHEDULE OF NON-CASH TRANSACTIONS
Common stock issued for convertible notes and accrued interest		$	350,513			$	299,400

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

  

BIOSOLAR, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

 

1.

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information refer to the financial statements and footnotes thereto included in the Company's Form 10-K for the year ended December 31, 2017.

 

Going Concern

The accompanying condensed financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company has not generated revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern and appropriateness of using the going concern basis is dependent upon, among other things, additional cash infusion. The Company has historically obtained funds through private placements offerings of equity and debt. Management believes that it will be able to continue to raise funds through the sale of its securities to its existing shareholders and prospective new investors to meet the Company’s obligations as they become due, and to allow the development of its core of business. There is no assurance that the Company will be able to continue raising the required capital for its operations.

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

 

Revenue Recognition

The Company will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured. To date, the Company has not had significant revenues and is in the development stage.

 

Cash and Cash Equivalent

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

 

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements, include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, derivative liabilities and the fair value of stock options. Actual results could differ from those estimates.

 

Intangible Assets

The Company has patent applications to protect the inventions and processes behind its proprietary bio-based back-sheet, a protective covering for the back of photovoltaic solar modules traditionally made from petroleum-based film. Intangible assets that have finite useful lives continue to be amortized over their useful lives

 

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for an equity award based on the grant-date fair value of the award. All grants under our stock-based compensation programs are accounted for at fair value and that cost is recognized over the period during which an employee, consultant, or director are required to provide service in exchange for the award (the vesting period). Compensation expense for options granted to employees and non-employees is determined in accordance with the standard as the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation expense for awards granted is re-measured each period.

 

Determining the appropriate fair value of the stock-based compensation requires the input of subjective assumptions, including the expected life of the stock-based payment and stock price volatility.  The Company used Black Scholes to value its stock option awards which incorporated the Company’s stock price, volatility, U.S. risk-free rate, dividend rate, and estimated life. The stock options terminate seven (7) years from the date of grant or upon termination of employment. As of June 30, 2018, 15,950,000 stock options are outstanding.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Net Earnings (Loss) per Share Calculations 

Net earnings (Loss) per share dictates the calculation of basic earnings (loss) per share and diluted earnings per share. Basic earnings (loss) per share are computed by dividing by the weighted average number of common shares outstanding during the year. Diluted net earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the effect of stock options and stock based awards (Note 4), plus the assumed conversion of convertible debt (Note 5).   

  

For the six months ended June 30, 2018, the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company has excluded 15,950,000 stock options and the shares issuable from convertible debt of $2,436,220, because their impact was anti-dilutive.

 

For the six months ended June 30, 2017, the Company’s diluted loss per share is the same as the basic loss per share, and the inclusion of any potential shares would have had an anti-dilutive effect due to the Company generating a loss. The Company has excluded 15,975,000 stock options and warrants of 150,000, and the shares issuable from convertible debt of $2,010,250, because their impact was anti-dilutive.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2018, the amounts reported for cash, inventory, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

	●	Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
	●	Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
	●	Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at June 30, 2018:

 

			Total				(Level 1)				(Level 2)				(Level 3)
	Derivative Liability		$	34,784,811			$	-			$	-			$	34,784,811
	Total Liabilities measured at fair value		$	34,784,811			$	-			$	-			$	34,784,811

 

The following is a reconciliation of the derivative liability for which Level 3 inputs were used in determining the approximate fair value:

 

	Balance as of December 31, 2017		$	5,239,073
	Fair value of derivative liabilities issued			80,844
	Loss on change in derivative liability			29,464,894
	Balance as of June 30, 2018		$	34,784,811

 

Reclassification of expenses

During the three and six month period ended June 30, 2017, certain reclassifications have been made to prior period expenses to conform to the current period presentation. There is no material impact on any of the Company’s previously issued financial statements.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

 

2.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

 

Recently Issued Accounting Pronouncements

In August 2017, FASB issued accounting standards update ASU-2017-12, “D” (Topic 815) – “Targeted Improvements to Accounting for Hedging Activities”, to require an entity to present the earnings effect of the hedging instrument in the same statement line item in which the earnings effect of the hedged item is reported. The amendments in this update are effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods with the fiscal years beginning after December 15, 2020. Early adoption is permitted in any interim period after issuance of the update. The Company is currently evaluating the impact of the adoption of ASU 2017-12 on the Company’s financial statements.

 

In June 2018, FASB issued accounting standards update ASU 2018-07, (Topic 505) – “Shared-Based Payment Arrangements with Nonemployees”, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees will be aligned with the requirements for share-based payments granted to employees. Under the ASU 2018-07, the measurement of equity-classified nonemployee share-based payments will be fixed on the grant date, as defined in ASC 718, and will use the term nonemployee vesting period, rather than requisite service period. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted if financial statements have not yet been issued. The Company is currently evaluating the impact of the adoption of ASU 2018-07 on the Company’s financial statements.

 

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

 

3.

CAPITAL STOCK

 

During the six months ended June 30, 2018, the Company issued 15,445,341 shares of common stock upon conversion of convertible promissory notes in the amount of $85,410, plus accrued interest of $30,370, with an aggregate fair value loss of $234,733 at prices ranging from $0.0160 - $0.058.

 

4.

STOCK OPTIONS

 

Stock Options

The Company did not grant any stock options during the six months ended June 30, 2018 and 2017, respectively.

 

			6/30/2018								6/30/2017
			Number of Options				Weighted average exercise price				Number of Options				Weighted average exercise price
	Outstanding as of the beginning of the periods			15,975,000			$	0.23				15,975,000			$	0.23
	Granted			-				-				-				-
	Exercised			-				-				-				-
	Expired			(25,000	)		$	0.40				-				-
	Outstanding as of the end of the periods			15,950,000			$	0.23				15,975,000			$	0.23
	Exercisable as of the end of the periods			15,950,000			$	0.23				13,815,000			$	0.23

  

The weighted average remaining contractual life of options outstanding as of June 30, 2018 and 2017 was as follows:

 

	6/30/2018																6/30/2017
	Exercisable Price				Stock Options Outstanding				Stock Options Exercisable				Weighted Average Remaining Contractual Life (years)				Exercisable Price				Stock Options Outstanding				Stock Options Exercisable				Weighted Average Remaining Contractual Life (years)
																	$	0.40				25,000				25,000				0.67
	$	0.09				2,450,000				2,450,000				3.73			$	0.09				2,450,000				2,450,000				4.73
	$	0.26				13,500,000				13,500,000				4.18			$	0.26				13,500,000				11,340,000				5.18
						15,950,000				15,950,000												15,975,000				13,815,000

 

The stock-based compensation expense recognized in the statement of operations during the six months ended June 30, 2018 and 2017, related to the granting of these options was $0 and $771,027, respectively.

 

As of June 30, 2018, and 2017, respectively, there was no intrinsic value with regards to the outstanding options.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

 

5.

CONVERTIBLE PROMISSORY NOTES

 

As of June 30, 2018, the outstanding convertible promissory notes net of debt discount are summarized as follows:

 

	Convertible Promissory Notes, net of debt discount		$	2,362,702
	Less current portion			157,699
	Total long-term liabilities		$	2,205,003

 

Maturities of long-term debt for the next five years are as follows:

 

	Year Ending June 30,		Amount
	2020		$	631,220
	2021			493,000
	2022			693,783
	2023			289,000
	2024			98,000
			$	2,205,003

  

At June 30, 2018, the $2,436,220 in convertible promissory notes had a remaining debt discount of $73,518, leaving a net balance of $2,362,702.

 

On May 2, 2014, the Company issued a 10% unsecured convertible note (the “May Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the convertible promissory note, the Company received a tranche in the amount of $50,000. On various dates, the Company received additional tranches in the aggregate sum of $450,000, for a total aggregate sum of $500,000. As of June 30, 2018, the remaining principal balance was $221,220. During the six months ended June 30, 2018, the Company issued 15,445,341 shares of common stock for principal in the amount of $85,410, plus accrued interest of $30,370, leaving a principal balance of $221,220. Each tranche matures eighteen (18) months from the effective date of each tranche, which was extended on January 12, 2016 to sixty (60) months, with maturity dates ranging from June 12, 2019 to December 21, 2019. The May Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the average three (3) lowest trading prices of three (3) separate trading days recorded after the effective date, or c) the lowest effective price granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the timeframe of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the May Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche.

 

On January 30, 2015, the Company issued a 10% unsecured convertible note (the “January Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the convertible promissory note, the Company received a tranche in the amount of $50,000. On various dates, the Company received additional tranches in the aggregate sum of $450,000. The principal balance at June 30, 2018 was $500,000. Each tranche matured eighteen (18) months from the effective date of each tranche, which was extended on January 12, 2016 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from January 29, 2020 to August 25, 2020. The January Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.15 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the January Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the timeframe of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the January Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

 

5.

CONVERTIBLE PROMISSORY NOTES (Continued)

 

On October 1, 2015, the Company issued a 10% unsecured convertible note (the “October Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the convertible promissory note, the Company received a tranche in the amount of $90,000. On various dates, the Company received additional tranches in the aggregate sum of $395,000. The principal balance at June 30, 2018 was $485,000. Each tranche matures twelve (12) months from the effective date of each tranche, which was extended on October 13, 2016 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from October 1, 2020 to March 9, 2021.The October Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.25 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the October Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the timeframe of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the January Note has been determined by using the Binomial lattice formula with an expected life of sixty (60) months from the effective date of each tranche. The fair value of the October Note has been determined by using the Binomial lattice formula with an expected life of twelve (12) months.

 

On April 5, 2016, the Company issued a 10% unsecured convertible note (the “April Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the convertible promissory notes, the Company received a tranche in the amount of $48,000. On various dates, the Company received additional tranches in the aggregate sum of $452,000. The principal balance at June 30, 2018 was $500,000. Each tranche matures twelve (12) months from its’ effective date of each tranche, which was extended on April 5, 2017 to sixty (60) months from the effective date of each tranche, with maturity dates ranging from April 8, 2021 to February 20, 2022. The April Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the April Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the timeframe of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the April Note has been determined by using the Binomial lattice formula with an expected life of twelve (12) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $351 during the six months ended June 30, 2018.

 

On March 20, 2017, the Company issued a 10% unsecured convertible note (the “March Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the convertible promissory note, the Company received a tranche in the amount of $25,000. On various dates during the Company received additional tranches in the aggregate sum of $475,000. The principal balance as of June 30, 2018 was $500,000. Each tranche matures twelve (12) months from the effective date of each tranche, with an extension of sixty (60) months from each tranche. The March Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.13 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the March Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the timeframe of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the March Note has been determined by using the Binomial lattice formula with an expected life of twelve (12) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $4,556 during the six months ended June 30, 2018.

 

On February 26, 2018, the Company issued a 10% unsecured convertible note (the “February Note”) in the aggregate principal amount of up to $500,000, to be advanced in amounts at the lender’s discretion. Upon execution of the convertible promissory note, the Company received a tranche in the amount of $15,000. On various dates during the period ended June 30, 2018, Company received additional tranches in the aggregate sum of $215,000. The principal balance as of June 30, 2018 was $230,000. Each tranche matures twelve (12) months from the effective date of each tranche, with an extension of sixty (60) months from each tranche. The February Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of a) the lesser of $0.03 per share of common stock, b) fifty percent (50%) of the lowest trade price recorded since the original effective date of the February Note, or c) the lowest effective price per share granted to any person or entity after the effective date to acquire common stock. If the Borrower fails to deliver shares in accordance with the timeframe of three (3) business days, the Lender, at any time prior to selling all of those shares, may rescind any portion, in whole or in part of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to the Borrower. In addition, for each conversion, in the event that shares are not delivered by the fourth business day (inclusive of the day of conversion), a penalty of $1,500 per day shall be assessed for each day after the third business day (inclusive of the day of the conversion) until the shares are delivered. The fair value of the February Note has been determined by using the Binomial lattice formula with an expected life of twelve (12) months. The Company recorded amortization of debt discount, which was recognized as interest expense in the amount of $8,110 during the six months ended June 30, 2018.

 

 

BIOSOLAR, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS – UNAUDITED

FOR THE SIX MONTHS ENDED JUNE 30, 2018 AND 2017

 

5.

CONVERTIBLE PROMISSORY NOTES (Continued)

 

We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations.

 

6.

DERIVATIVE LIABILITIES

 

We evaluated the financing transactions in accordance with ASC Topic 815, Derivatives and Hedging, and determined that the conversion feature of the convertible promissory note was not afforded the exemption for conventional convertible instruments due to its variable conversion rate. The note has no explicit limit on the number of shares issuable so they did not meet the conditions set forth in current accounting standards for equity classification. The Company elected to recognize the note under paragraph 815-15-25-4, whereby, there would be a separation into a host contract and derivative instrument. The Company elected to initially and subsequently measure the note in its entirety at fair value, with changes in fair value recognized in earnings. The Company recorded a derivative liability representing the imputed interest associated with the embedded derivative. The derivative liability is adjusted periodically per the stock price fluctuations.

 

The convertible notes issued and described in Note 5 do not have fixed settlement provisions because their conversion prices are not fixed. The conversion feature has been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations.

 

During the six months ended June 30, 2018, as a result of the convertible notes (“Notes”) issued that were accounted for as derivative liabilities, we determined that the fair value of the conversion feature of the convertible notes at issuance was $80,844, based upon a Binomial-Model calculation. We recorded the full value of the derivative as a liability at issuance with an offset to valuation discount, which will be amortized over the life of the Notes.

 

During the six months ended June 30, 2018, the Company converted $85,410 in principal of convertible notes, plus accrued interest of $30,370. As a result of the conversion of these notes the Company recorded a fair value loss on the settlement of debt in the amount of $234,733 in the statement of operations for the six months ended June 30, 2018. At June 30, 2018, the fair value of the derivative liability was $34,784,811.

 

For purpose of determining the fair market value of the derivative liability for the embedded conversion, the Company used the Binomial lattice valuation model. The significant assumptions used in the Binomial lattice valuation model for the derivative are as follows:

 

				6/30/2018
	Risk free interest rate			2.09% - 2.73	%
	Stock volatility factor			83.0% - 196.0	%
	Weighted average expected option life			1 years - 5 years
	Expected dividend yield			None

 

7.

SUBSEQUENT EVENT

 

Management has evaluated subsequent events according to the requirements of ASC TOPIC 855 and has determined that there are the following subsequent events:

 

On July 23, 2018, the Company entered into a convertible promissory note with an investor, providing for the sale by the Company of a 10% unsecured convertible note (the “July Note”) in the principal amount of $63,000. The July Note is convertible into shares of common stock of the Company at a price equal to a variable conversion price of 61% of the average lowest two (2) trading prices for common stock during the fifteen (15) trading day period prior to the conversion date.

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Special Note on Forward-Looking Statements.

 

Certain statements in “Management’s Discussion and Analysis or Plan of Operation” below, and elsewhere in this quarterly report, are not related to historical results, and are forward-looking statements. Forward-looking statements present our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements frequently are accompanied by such words such as “may,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” or the negative of such terms or other words and terms of similar meaning. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, achievements, or timeliness of such results. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such forward-looking statements. We are under no duty to update any of the forward-looking statements after the date of this quarterly report. Subsequent written and oral forward looking statements attributable to us or to persons acting in our behalf are expressly qualified in their entirety by the cautionary statements and risk factors set forth in our annual report on Form 10-K filed with the SEC on March 19, 2018, as amended March 20, 2018, and in other reports filed by us with the SEC.

 

You should read the following description of our financial condition and results of operations in conjunction with the financial statements and accompanying notes included in this report.

 

Overview

 

We are developing innovative technologies to increase the capacity and reduce the cost of storing electrical energy. We have previously developed an innovative material technology to reduce the cost per watt of electricity produced by Photovoltaic, or PV, solar modules.

 

We are currently working on a silicon anode additive material technology intended to drastically increase the storage capacity of current and future generation of lithium-ion batteries while lowering the cost of storing electrical energy. The lower cost of electrical energy storage will result in reduced cost per watt of electricity produced by PV solar modules as well.

 

We were incorporated in the State of Nevada on April 24, 2006, as BioSolar Labs, Inc. Our name was changed to BioSolar, Inc. on June 8, 2006. Our principal executive offices are located at 27936 Lost Canyon Road, Suite 202, Santa Clarita, California 91387, and our telephone number is (661) 251-0001. Our fiscal year end is December 31.

 

Recent Transactions

 

None.

 

Application of Critical Accounting Policies

 

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to impairment of property, plant and equipment, intangible assets, deferred tax assets and fair value computation using a Binomial lattice valuation model. We base our estimates on historical experience and on various other assumptions, such as the trading value of our common stock and estimated future undiscounted cash flows, that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions; however, we believe that our estimates, including those for the above-described items, are reasonable.

 

 

Use of Estimates

 

In accordance with accounting principles generally accepted in the United States, management utilizes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. These estimates and assumptions relate to recording net revenue, collectability of accounts receivable, useful lives and impairment of tangible and intangible assets, accruals, income taxes, inventory realization, stock-based compensation expense and other factors. Management believes it has exercised reasonable judgment in deriving these estimates. Consequently, a change in conditions could affect these estimates.

 

Fair Value of Financial Instruments

 

Our cash, cash equivalents, investments, inventory, prepaid expenses, and accounts payable are stated at cost which approximates fair value due to the short-term nature of these instruments.

 

Recently Issued Accounting Pronouncements

 

Management reviewed currently issued pronouncements during the six months ended June 30, 2018, and does not believe that any other recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying condensed financial statements.

 

Results of Operations – Three Months Ended June 30, 2018 Compared to the Three Months Ended June 30, 2017

 

OPERATING EXPENSES 

 

General and Administrative Expenses

 

General and administrative (“G&A”) expenses decreased by $368,795 to $107,677 for the three months ended June 30, 2018, compared to $476,472 for the prior period ended June 30, 2017. This decrease in G&A expenses was the result of a decrease in non-cash stock compensation expense of $378,085, with a decrease in investor relations of $15,862, and an overall increase of $25,152 in other G&A expenses.

 

Research and Development

 

Research and Development (“R&D”) expenses decreased by $1,967 to $40,041 for the three months ended June 30, 2018, compared to $42,008 for the prior period ended June 30, 2017. This overall decrease in R&D expenses was the result of a decrease in contracting of outside services.

 

Other Income/(Expenses)

 

Other income and (expenses) increased by $(28,257,836) to $(29,407,760) for the three months ended June 30, 2018, compared to $(1,149,924) for the prior period ended June 30, 2017. The increase in other income and (expenses) was the result of an increase in non-cash loss on change in fair value of the derivative instruments of $28,448,188, a decrease in interest expense of $16,646, which includes non-cash expense of amortization of debt discount in the amount of $27,622, and a decrease in interest income of $3, with a decrease in fair value loss on settlement of debt of $173,709. The decrease in other income and (expenses) was primarily due to the net change in the fair value of the derivative instruments and amortization of debt discount.

 

Net Income (Loss)

 

Our net loss for the three months ended June 30, 2018 was $(29,557,287), compared to net loss of $(1,669,235) for the prior period ended June 30, 2017. The increase in net loss was due to an increase in non-cash other income (expenses) associated with the net change in derivative instruments, and an overall decrease in operating expenses. The Company has not generated any revenues.

 

 

Results of Operations – Six Months Ended June 30, 2018 Compared to the Six Months Ended June 30, 2017

 

OPERATING EXPENSES 

 

General and Administrative Expenses

 

General and administrative (“G&A”) expenses decreased by $769,562 to $203,608 for the six months ended June 30, 2018, compared to $973,170 for the prior period ended June 30, 2017. This decrease in G&A expenses was the result of a decrease in non-cash stock compensation expense of $771,027, with a decrease in professional fees of $5,878, and an overall increase of $7,343 in other G&A expenses.

 

Research and Development

 

Research and Development (“R&D”) expenses increased by $31,882 to $93,441 for the six months ended June 30, 2018, compared to $61,559 for the prior period ended June 30, 2017. This overall decrease in R&D expenses was the result of a decrease in contracting of outside services.

 

Other Income/(Expenses)

 

Other income and (expenses) increased by $(28,825,487) to $(29,829,215) for the six months ended June 30, 2018, compared to $(1,003,728) for the prior period ended June 30, 2017. The increase in other income and (expenses) was the result of an increase in non-cash loss on change in fair value of the derivative instruments of $28,929,804, a decrease in interest expense of $94,092, which includes non-cash expense of amortization of debt discount in the amount of $115,585, and a decrease in interest income of $9, with an increase in fair value loss on settlement of debt of $10,234. The decrease in other income and (expenses) was primarily due to the net change in the fair value of the derivative instruments and amortization of debt discount.

 

Net Income (Loss)

 

Our net loss for the six months ended June 30, 2018 was $(30,129,607), compared to a net loss of $(2,040,118) for the prior period ended June 30, 2017. The increase in net loss was due to an increase in non-cash other income (expenses) associated with the net change in derivative instruments, and an overall decrease in operating expenses. The Company has not generated any revenues.

 

  

LIQUIDITY AND CAPITAL RESOURCES

 

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

 

The condensed financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities and commitments in the normal course of business. The accompanying condensed financial statements do not reflect any adjustments that might result if we are unable to continue as a going concern. During the six months ended June 30, 2018, we did not generate any revenues, incurred a net loss of $30,129,607, and used cash of $328,736 in operations. As of June 30, 2018, we had a working capital deficiency of $35,308,986 and a shareholders’ deficit of $37,433,629. These factors, among others, raise substantial doubt about our ability to continue as a going concern.

 

In the six months ended June 30, 2018, we obtained funding through the sale of our securities. Management believes that we will be able to continue to raise funds through the sale of our securities to existing and new investors. Management believes that funding from existing and prospective new investors and future revenue will provide the additional cash needed to meet our obligations as they become due, and will allow the development of our core business operations.

 

As of June 30, 2018, we had a working capital deficit of $35,308,986 compared to a working capital deficit of $5,941,190 for the year ended December 31, 2017. This increase in capital deficit of $29,367,796 was due primarily to a decrease in cash, and accounts payable, with an increase in prepaid expenses, accrued expenses, derivative liability associated with our outstanding promissory notes, and an increase in the issuance of convertible promissory notes.

 

During the six months ended June 30, 2018, we used $328,735 of cash for operating activities, as compared to $280,076 for the prior period ended June 30, 2017. The increase in the use of cash for operating activities for the current period was a result of an increase in research and development cost, and insurance expense, compared to the prior six months ended June 30, 2017.

 

Cash used in investing activities for the six months ended June 30, 2018 and 2017, were $5,770 and $482, respectively. The overall net change in investing activities was primarily due to an increase in the purchase of equipment in the current period.

 

Cash provided from financing activities was $328,000 for the six months ended June 30, 2018, as compared to $253,000 for the prior period ended June 30, 2017. The increase in financing was due to an increase in convertible promissory notes. The convertible notes are convertible into shares of common stock, which have limitations on conversion. The lender is limited to no more than a 4.99% beneficial ownership of the outstanding shares of common stock. Beneficial ownership is determined in accordance with Section 13D-G. Our ability to continue as a going concern is dependent upon raising capital through financing transactions and future revenue. Our capital needs have primarily been met from the proceeds of private placement of our securities, as we currently have not generated any revenues.

 

Our independent auditors, in their report on our audited financial statements for the year ended December 31, 2017, expressed substantial doubt about our ability to continue as a going concern. Our financial statements as of June 30, 2018 have been prepared under the assumption that we will continue as a going concern. Our ability to continue as a going concern ultimately is dependent upon our ability to generate revenue, which is dependent upon our ability to obtain additional equity or debt financing, attain further operating efficiencies and, ultimately, to achieve profitable operations. Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

  

PLAN OF OPERATION AND FINANCING NEEDS

 

We are engaged in the development of innovative technologies that increase the capacity and reduce the cost of storing electrical energy. We are currently focusing on developing a high capacity silicon alloy anode material technology to increase the storage capacity and reduce cost of the current and future generation of lithium-ion batteries by 2019.  

 

Our plan of operation within the next six months is to utilize our cash balances to develop our silicon-based anode technology for high capacity, high density, and low cost Lithium-ion batteries.  We believe that our current cash and investment balances will be sufficient to support development activity and general and administrative expenses for the next three months. Management estimates that it will require additional cash resources during 2018, based upon its current operating plan and condition. We expect increased expenses during the third quarter of 2018 as we ramp up prototyping efforts for Lithium-ion batteries incorporating our electrode material.  We will be investigating additional financing alternatives, including equity and/or debt financing. There is no assurance that capital in any form would be available to us, and if available, on terms and conditions that are acceptable. If we are unable to obtain sufficient funds during the next fifteen months, we may be forced to reduce the size of our organization, which could have a material adverse impact on, or cause us to curtail and/or cease the development of our products

 

Off-Balance Sheet Arrangements

 

We do not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, result of operations, liquidity or capital expenditures.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

  

As a smaller reporting company, as that term is defined in Item 10(f)(1) of Regulation S-K, we are not required to provide information required by this Item. 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

As of the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of our chief executive officer and chief financial officer of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act). Based upon this evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Control over Financial Reporting

 

There was no change to our internal control over financial reporting that occurred during our second fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

PART II - OTHER INFORMATION

  

ITEM 1. LEGAL PROCEEDINGS

 

We are not a party to any pending legal proceeding, nor is our property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of our business. None of our directors, officers or affiliates is involved in a proceeding adverse to our business or has a material interest adverse to our business.

 

ITEM 1A. RISK FACTORS

 

There are no material changes from the risk factors previously disclosed in the Registrant’s Form 10-K filed on March 19, 2018, as amended March 20, 2018.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the three months ended June 30, 2018, the Company issued 6,741,070 shares of common stock at prices of $0.016 to $0.058 per share upon conversion of $26,980 in convertible promissory notes, including $9,930 in accrued interest.

 

The Company relied on an exemption pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, in connection with the foregoing issuance.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable

 

ITEM 5. OTHER INFORMATION

 

None

 

 

ITEM 6. EXHIBITS

 

Exhibit No.		Description
31.1		Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to Sarbanes-Oxley Section 302 (filed herewith).
32.1		Certification by Chief Executive Officer and Acting Chief Financial Officer pursuant to 18 U.S.C. Section 1350 (filed herewith).
EX-101.INS		XBRL Instance Document
EX-101.SCH		XBRL Taxonomy Extension Schema Document
EX-101.CAL		XBRL Taxonomy Extension Calculation Linkbase
EX-101.DEF		XBRL Taxonomy Extension Definition Linkbase
EX-101.LAB		XBRL Taxonomy Extension Labels Linkbase
EX-101.PRE		XBRL Taxonomy Extension Presentation Linkbase

 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Angeles, State of California, on July 31, 2018.

 

	BIOSOLAR, INC.
Date: August 1, 2018	By:	/s/ David Lee
		Chief Executive Officer (Principal Executive Officer) and Acting Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

18